FrancophonIA/ELRC3.0 huggingface dataset:
English: The hypotensive effects of dexmedetomidine may be of greater significance in those patients with preexisting hypotension (especially if not responsive to vasopressors), hypovolaemia, chronic hypotension or reduced functional reserve such as patients with severe ventricular dysfunction and the elderly and special care is warranted in these cases (see section 4.3).
Slovenian: Hipotenzivni učinki deksmedetomidina so lahko bolj pomembni pri tistih bolnikih, ki že imajo hipotenzijo (še posebej, če se ta ne odziva na uporabo vazopresorjev), hipovolemijo, kronično hipotenzijo ali zmanjšano funkcionalno rezervo, na primer pri bolnikih s hudo disfunkcijo ventriklov in pri starostnikih, zato je v teh primerih potrebna posebna previdnost (glejte poglavje 4.3).
English: There are three types of initial metabolic reactions; direct N-glucuronidation, direct N-methylation and cytochrome P450 catalysed oxidation.
Slovenian: Obstajajo tri vrste začetnih presnovnih reakcij: neposredna N-glukuronidacija, neposredna N-metilacija in oksidacija, katalizirana s citokromom P450.
English: The time to recovery after the use of dexmedetomidine was reported to be approximately one hour.
Slovenian: Poročali so, da traja okrevanje po uporabi deksmedetomidina približno eno uro.
English: If you are using medicines which lower your blood pressure and heart rate, co-administration with Dexdor may enhance this effect.
Slovenian: Če jemljete zdravila, ki znižujejo krvni tlak in hitrost srčnega utripa, lahko sočasna uporaba zdravila Dexdor okrepi ta učinek.
English: The pharmacokinetics of dexmedetomidine is linear in the dosing range from 0.2 to 1.4 µg/kg/h and it does not accumulate in treatments lasting up to 14 days.
Slovenian: Farmakokinetika deksmedetomidina je linearna v razponu odmerkov od 0,2 do 1,4 µg/kg/h in v času do 14-dnevnega zdravljenja se deksmedetomidin ne kopiči.
English: During the current reporting period 16 March 2017 - 15 Mar 2018, the market authorisation holder, Orion pharma undertook a cumulative review of all reports of the adverse reaction of hyperthermia Their review identified 172 reports, 91 of which were serious and 81 of which were non-serious.
Slovenian: V sedanjem obdobju poročanja, od 16. marca 2017 do 15. marca 2018 je imetnik dovoljenja za promet z zdravilom Orion Pharma opravil kumulativni pregled vseh poročil o neželenemu učinku hipertermiji.
English: Dexmedetomidine may reduce cerebral blood flow and intracranial pressure and this should be considered when selecting therapy.
Slovenian: Deksmedetomidin lahko zmanjša pretok krvi skozi možgane in intrakranialni tlak, kar je treba upoštevati pri izbiri zdravljenja.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/11/718/001-002, EU/1/11/718/004, EU/1/11/718/006-007
Slovenian: EU/1/11/718/001-002, EU/1/11/718/004, EU/1/11/718/006-007
English: Available data suggest that the formation of the oxidised metabolites is mediated by several CYP forms (CYP2A6, CYP1A2, CYP2E1, CYP2D6 and CYP2C19).
Slovenian: Podatki, ki so na voljo, kažejo, da na nastanek oksidiranih presnovkov vpliva več izoencimov CYP (CYP2A6, CYP1A2, CYP2E1, CYP2D6 in CYP2C19).
English: The symptoms responded to leg raising and anticholinergics such as atropine or glycopyrrolate.
Slovenian: Te simptome so odpravili z dvigom nog in z antiholinergiki, kot sta atropin ali glikopirolat.
English: - The other ingredients are sodium chloride and water for injections.
Slovenian: - Druge pomožne snovi so natrijev klorid in voda za injekcije.
English: No human data on fertility are available.
Slovenian: Ni podatkov o vplivu na plodnost pri ljudeh.
English: Reduced fetal body weight was noted also in the rat fertility study at dose 18 µg/kg/day and was accompanied with delayed ossification at dose 54 µg/kg/day.
Slovenian: Tudi v študiji plodnosti pri podganah so opazili zmanjšano telesno maso plodov pri odmerkih 18 µg/kg/dan, ki jo je spremljala zapoznela osifikacija pri odmerku 54 µg/kg/dan.
English: Although dexmedetomidine is dosed to effect, it is advisable to use components with synthetic or coated natural rubber gaskets.
Slovenian: Čeprav se deksmedetomidin odmerja glede na učinek, je torej priporočljivo, da uporabljate pripomočke s tesnili iz sintetične ali obložene naravne gume.
English: Studies from outside the ICU have confirmed that Dexdor can be administered safely to patients without endotracheal intubation provided adequate monitoring is in place.
Slovenian: Študije, opravljene zunaj oddelkov za intenzivno nego, so potrdile, da se lahko zdravilo Dexdor varno uporablja tudi pri bolnikih brez endotrahealne intubacije, pod pogojem, da se jih ustrezno nadzira.
English: Subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C) had decreased hepatic clearance of dexmedetomidine and prolonged plasma elimination t1/2.
Slovenian: Preiskovanci z različnimi stopnjami jetrne okvare (razreda A, B ali C po Child-Pughu) imajo zmanjšan jetrni očistek deksmedetomidina in podaljšano razpolovno dobo izločanja iz plazme t1/2.
English: Most dexmedetomidine patients required no additional sedative treatment.
Slovenian: Večina bolnikov, ki so prejemali deksmedetomidin, ni potrebovala zdravljenja z nobenim dodatnim sedativom.
English: The following medicines may enhance the effect of Dexdor: - medicines that help you sleep or cause sedation (e.g. midazolam, propofol) - strong pain medicines (e.g. opioids such as morphine, codeine) - anaesthetic medicines (e.g. sevoflurane, isoflurane)
Slovenian: Naslednja zdravila lahko okrepijo učinek zdravila Dexdor: - zdravila, ki pomagajo spati ali povzročajo sedacijo (npr. midazolam, propofol), - močna protibolečinska zdravila (npr. opioidi, kot sta morfin in kodein),
English: Patients should be monitored continuously for early signs of hypotension, hypertension, bradycardia, respiratory depression, airway obstruction, apnoea, dyspnoea and/or oxygen desaturation (see section 4.8).
Slovenian: Bolnike je treba kontinuirano spremljati glede zgodnjih znakov hipotenzije, hipertenzije, bradikardije, respiratorne depresije, obstrukcije dihalnih poti, apneje, dispneje in/ali desaturacije kisika (glejte poglavje 4.8).
English: Dexdor should not be used during pregnancy or breast-feeding unless clearly necessary.
Slovenian: Zdravila Dexdor ne smemo uporabljati v času nosečnosti ali dojenja, razen če je to nujno potrebno.
English: Care should be taken in severe hepatic impairment as excessive dosing may increase the risk of adverse reactions, over-sedation or prolonged effect as a result of reduced dexmedetomidine clearance.
Slovenian: Bolniki z jetrno okvaro Potrebna je previdnost pri hudi jetrni okvari, ker prekomerno odmerjanje lahko poveča tveganje za neželene reakcije, preveliko sedacijo ali podaljšani učinek kot posledico zmanjšanega očistka deksmedetomidina.
English: Keep the ampoules or vials in the outer carton in order to protect from light.
Slovenian: Ampule ali viale shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
English: Experience of dexmedetomidine in severe neurological disorders such as head injury and after neurosurgery is limited and it should be used with caution here, especially if deep sedation is required.
Slovenian: Izkušenj z uporabo deksmedetomidina pri hudih nevroloških boleznih, na primer pri poškodbah glave in po nevrokirurških posegih, je malo in je treba zdravilo pri takšnih bolnikih uporabljati previdno, še posebej če je potrebna globoka sedacija.
English: The maintenance infusion of study drug could be titrated from 0.2 µg/kg/h to 1 µg/kg/h.
Slovenian: Vzdrževalno infuzijo testiranega zdravila se lahko titrira od 0,2 μg/kg/h do 1 μg/kg/h.
English: Dexmedetomidine binds to both human serum albumin and Alpha-1-acid glycoprotein with serum albumin as the major binding protein of dexmedetomidine in plasma.
Slovenian: Deksmedetomidin se veže tako na človeški serumski albumin kot na alfa-1-kisli glikoprotein, pri čemer je serumski albumin poglavitna vezavna beljakovina deksmedetomidina v plazmi.
English: Grounds for the variation to the terms of the marketing authorisation(s) On the basis of the scientific conclusions for dexmedetomidine the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing dexmedetomidine is unchanged subject to the proposed changes to the product information The CHMP recommends that the terms of the marketing authorisation(s) should be varied.
Slovenian: Podlaga za spremembe pogojev dovoljenja (dovoljenj) za promet z zdravilom Na podlagi znanstvenih zaključkov za deksmedetomidin odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) deksmedetomidin nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
English: When Dexdor is administered for conscious sedation, patients should be continuously monitored by persons not involved in the conduct of the diagnostic or surgical procedure.
Slovenian: Ko se zdravilo Dexdor uporablja za sedacijo pri ohranjeni zavesti, morajo bolnike stalno nadzorovati osebe, ki niso vključene v izvajanje diagnostičnega ali kirurškega posega.
English: 2, 5 or 10 ml Type I glass vials (with filling volumes of 2, 4 and 10 ml), grey bromobutyl rubber closure with fluoropolymer coating
Slovenian: 2, 5 ali 10 ml viale iz stekla tipa I (s polnilnim volumnom 2, 4 ali 10 ml), siva zaporka iz bromobutilne gume s fluoropolimerno oblogo
English: The sedative effects are mediated through decreased firing of locus coeruleus, the predominant noradrenergic nucleus, situated in the brainstem.
Slovenian: Sedativno delovanje se doseže z zmanjšanim proženjem impulzov iz locus ceruleusa, poglavitnega noradrenergičnega jedra, ki se nahaja v možganskem deblu.
English: Dexmedetomidine normally does not cause deep sedation and patients may be easily roused.
Slovenian: Deksmedetomidin običajno ne povzroča globoke sedacije in bolnike se lahko hitro zbudi.
English: Elderly patients over 65 years of age may be more prone to hypotension with the administration of dexmedetomidine, including a loading dose, for procedures.
Slovenian: Starejši bolniki, ki imajo več kot 65 let, so lahko bolj nagnjeni k hipotenziji pri uporabi deksmedetomidina, vključno z udarnim odmerkom za proceduralno sedacijo.
English: In relatively healthy non-ICU subjects treated with dexmedetomidine, bradycardia has occasionally led to sinus arrest or pause.
Slovenian: Pri sorazmerno zdravih preiskovancih, ki niso bili na oddelku za intenzivno nego in so jih zdravili z deksmedetomidinom, je bradikardija občasno vodila do sinusnega zastoja ali pavze.
English: The major urinary metabolites are the two isomeric N-glucuronides, which together accounted for approximately 34% of the dose and N-methyl 3-hydroxymethyl dexmedetomidine O-glucuronide that accounted for 14.51% of the dose.
Slovenian: Poglavitna presnovka v urinu sta dva izomerna N-glukuronida, ki skupaj predstavljata približno 34 % odmerka, in N-metil 3-hidroksimetil deksmedetomidin O-glukuronid, ki predstavlja 14,51 % odmerka.
English: Hypertension has been associated with the use of a loading dose and this reaction can be reduced by avoiding such a loading dose or reducing the infusion rate or size of the loading dose.
Slovenian: Hipertenzija je povezana z uporabo udarnega odmerka zato to reakcijo lahko zmanjšamo z izogibanjem uporabi udarnega odmerka ali z zmanjšanjem hitrosti infundiranja ali velikosti udarnega odmerka.
English: The most common adverse reactions reported in conjunction with overdose include bradycardia, hypotension, hypertension, oversedation, respiratory depression and cardiac arrest.
Slovenian: Med najpogostejše neželene učinke, ki so jih poročali v povezavi s prevelikim odmerjanjem, sodijo bradikardija, hipotenzija, hipertenzija, čezmerna sedacija, depresija dihanja in srčni zastoj.
English: After dilution Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.
Slovenian: Po redčenju Kemična in fizikalna stabilnost zdravila med uporabo je bila dokazana za 24 ur pri temperaturi 25 °C.
English: 1000 mcg/ 10 ml
Slovenian: 1000 µg/10 ml
English: Dexdor should not be used as a general anaesthetic induction agent for intubation or to provide sedation during muscle relaxant use.
Slovenian: Zdravila Dexdor ne sme uporabljati za indukcijo v splošno anestezijo pri intubaciji ali za sedacijo pri uporabi mišičnih relaksansov.
English: To maintain a Ramsay Sedation Scale ≥2 53% of the patients receiving dexmedetomidine did not require midazoloam rescue vs. 14% of patients receiving placebo.
Slovenian: Za ohranitev stopnje sedacije ≥ 2 po Ramsayjevi lestvici 53 % bolnikov, ki so prejemali deksmedetomidin, ni potrebovalo rešilnega zdravljenja z midazolamom v primerjavi s 14 % bolnikov, ki so prejemali placebo.
English: Dexmedetomidine reduces heart rate and blood pressure through central sympatholysis but at higher concentrations causes peripheral vasoconstriction leading to hypertension (see section 5.1).
Slovenian: Srčno-žilni učinki in previdnostni ukrepi Deksmedetomidin zmanjšuje srčno frekvenco in krvni tlak prek centralne simpatikolize, pri večjih koncentracijah pa povzroča periferno vazokonstrikcijo, ki vodi do hipertenzije (glejte poglavje 5.1).
English: New-born infants may be particularly sensitive to the bradycardic effects of Dexdor in the presence of hypothermia and in conditions of heart rate-dependent cardiac output.
Slovenian: Novorojenčki so lahko še posebej občutljivi za bradikardne učinke zdravila Dexdor v primeru hipotermije in pri stanjih, ko je srčni minutni volumen odvisen od srčne frekvence.
English: The mean percentage of unbound dexmedetomidine in plasma ranged from 8.5% in healthy subjects to 17.9% in subjects with severe hepatic impairment.
Slovenian: Srednji odstotek nevezanega deksmedetomidina v plazmi se giblje v razponu od 8,5 % pri zdravih preiskovancih do 17,9 % pri preiskovancih s hudo jetrno okvaro.
English: Dexmedetomidine lacks the anticonvulsant action of some other sedatives and so will not suppress underlying seizure activity.
Slovenian: Deksmedetomidin nima antikonvulzivnega delovanja nekaterih drugih sedativov in tako ne zavira osnovne epileptične aktivnosti.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 200 mcg/ 2 ml
Slovenian: VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 200 µg/2 ml
English: The adverse reactions listed in Table 1 have been accumulated from pooled data of clinical trials in intensive care.
Slovenian: Neželeni učinki, ki so podani v Preglednici 1, so zbrani iz združenih podatkov kliničnih preskušanj na oddelkih intenzivne nege.
English: Although dexmedetomidine is administered to effect, it may be necessary to consider initial/maintenance dose reduction in patients with hepatic impairment depending on the degree of impairment and the response.
Slovenian: Čeprav se deksmedetomidin odmerja glede na učinek, bo lahko potrebno zmanjšati začetni/vzdrževalni odmerek zdravila pri bolnikih z jetrno okvaro, odvisno od stopnje okvare in od bolnikovega odziva.
English: Therefore the PRAC recommends a more prominent warning that dexmedetomidine should not be used in malignant hyperthermia-sensitive patients.
Slovenian: Zato odbor PRAC priporoča dodatek bolj jasnega opozorila, da se deksmedetomidina ne sme uporabljati pri bolnikih, ki so nagnjeni h nastanku maligne hipertermije.
English: Co-administration of dexmedetomidine with anaesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects, including sedative, anaesthetic and cardiorespiratory effects.
Slovenian: Sočasna uporaba deksmedetomidina z anestetiki, sedativi, hipnotiki in opioidi bo verjetno vodila do okrepitve učinkov zdravil, vključno z sedativnimi, anestetičnimi in kardiorespiratornimi učinki.
English: In double blind comparator controlled ICU studies the incidence of cortisol suppression in patients treated with dexmedetomidine (n=778) was 0.5% compared with 0% in patients treated with either midazolam (n=338) or propofol (n=275).
Slovenian: V dvojno slepih primerjalno nadzorovanih študijah na oddelku za intenzivno nego je bila incidenca supresije kortizola pri bolnikih, ki so bili sedirani z deksmedetomidinom (n=778) 0,5 % v primerjavi z 0 % pri bolnikih, ki so bili sedirani z midazolamom (n=338) ali propofolom (n=275).
English: Myocardial ischaemia or infarction, tachycardia
Slovenian: miokardna ishemija ali infarkt, tahikardija
English: A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer(s) responsible for batch release Orion Corporation
Slovenian: Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serije Orion Corporation
English: No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil and midazolam have been demonstrated.
Slovenian: Dokazane niso bile nobene farmakokinetične interakcije med deksmedetomidinom in izofluranom, propofolom, alfentanilom in midazolamom.
English: In the rat fertility study, dexmedetomidine had no effect on male or female fertility.
Slovenian: V študiji plodnosti pri podganah deksmedetomidin ni imel nobenega učinka na plodnost samcev ali samic.
English: The solution should be shaken gently to mix well.
Slovenian: Raztopino nežno pretresite, da se dobro premeša.
English: There are no or limited amount of data from the use of dexmedetomidine in pregnant women.
Slovenian: Podatkov o uporabi deksmedetomidina pri nosečnicah ni oziroma so omejeni.
English: Orion pharma noted that case reports of overdose are frequently associated with ADRs of bradycardia, hypotension, over sedation, cardiac arrest, respiratory depression and hypertension so proposed to reinforce the existing warnings in section 4.9 of the SmPC and to include the adverse reaction of hypertension, and to redefine somnolence as respiratory depression.
Slovenian: Pri družbi Orion Pharma so ugotovili, da so primeri prevelikega odmerjanja pogosto povezani z naslednjimi neželenimi učinki: bradikardijo, hipotenzijo, čezmerno sedacijo, srčnim zastojem, depresijo dihanja in hipertenzijo, zato so predlagali okrepitev obstoječih opozoril v poglavju 4.9 Povzetka glavnih značilnosti zdravila in vključitev neželenega učinka hipertenzije, ter ponovno opredelitev zaspanosti in depresije dihanja.
English: The minor metabolites dexmedetomidine carboxylic acid, 3-hydroxymethyl dexmedetomidine and its Oglucuronide individually comprised 1.11 to 7.66% of the dose.
Slovenian: deksmedetomidin karboksilna kislina, 3-hidroksimetil deksmedetomidin in njegov O-glukuronid, so ločeno predstavljali od 1,11 do 7,66 % odmerka.
English: Dexmedetomidine is excreted in human milk, however levels will be below the limit of detection by 24 hours following treatment discontinuation.
Slovenian: Dexmedetomidin se izloča v materino mleko, vendar se njegova koncentracija 24 ur po prekinitvi zdravljenja zniža pod mejo detekcije.
English: For sedation of adult ICU (Intensive Care Unit) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).
Slovenian: Za sedacijo na oddelkih za intenzivno nego pri odraslih bolnikih, ki potrebujejo stopnjo sedacije največ do ravni, ko se zbujanje bolnika še da doseči z verbalno stimulacijo (kar ustreza Richmondovi lestvici agitacije - sedacije (RASS) 0 do -3).
English: Dexmedetomidine may induce hyperthermia that may be resistant to traditional cooling methods.
Slovenian: Deksmedetomidin lahko povzroči hipertermijo, ki je lahko odporna na uveljavljene metode hlajenja.
English: Dexdor can be diluted in glucose 50 mg/ml (5%), Ringers, mannitol or sodium chloride 9 mg/ml (0.9%) solution for injection to achieve the required concentration of either 4 micrograms/ml or 8 micrograms/ml prior to administration.
Slovenian: Zdravilo Dexdor lahko razredčite z glukozo 50 mg/ml (5 %), Ringerjevo raztopino, manitolom ali natrijevim kloridom 9 mg/ml (0,9 %) raztopino za injiciranje, da boste pred dajanjem zdravila bolniku dosegli potrebno koncentracijo bodisi 4 mikrograme/ml ali 8 mikrogramov/ml.
English: Dexmedetomidine was similar to midazolam (Ratio 1.07; 95% CI 0.971, 1.176) and propofol (Ratio 1.00; 95% CI 0.922, 1.075) on the time in target sedation range in a predominently medical population requiring prolonged light to moderate sedation (RASS 0 to -3) in the ICU for up to 14 days, reduced the duration of mechanical ventilation compared to midazolam and reduced the time to extubation compared to midazolam and propofol.
Slovenian: Deksmedetomidin je na podoben način kot midazolam (razmerje 1,07; 95 % IZ 0,971, 1,176) in propofol (razmerje 1,00; 95 % IZ 0,922, 1,075) po času v tarčnem razponu sedacije pri populaciji, ki je bila sestavljena pretežno iz bolnikov in pri kateri je bila na oddelku za intenzivno nego potrebna daljša blaga do zmerna sedacija (RASS od 0 do -3) v času do 14 dni, zmanjšal trajanje mehanične ventilacije v primerjavi z midazolamom in skrajšal čas do ekstubacije v primerjavi z midazolamom in propofolom.
English: Please see below in tabulated form the volumes needed to prepare the infusion.
Slovenian: V spodnji preglednici so podani volumni, ki so potrebni za pripravo infuzije.
English: - Hypotension (55 % in dexmedetomidine-group vs. 30 % in placebo-group receiving rescue midazolam and fentanyl) - Respiratory depression ( 38 % in dexmedetomidine-group vs. 35 % in placebo-group receiving rescue midazolam and fentanyl) - Bradycardia (14 % in dexmedetomidine-group vs. 4 % in placebo-group receiving rescue midazolam and fentanyl)
Slovenian: - hipotenzija (55 % v skupini, ki je prejemala deksmedetomidin, v primerjavi s 30 % v skupini, ki je prejemala placebo in rešilno zdravljenje z midazolamom ter fentanilom) - depresija dihanja (38 % pri skupini, ki je prejemala deksmedetomidin, v primerjavi s 35 % v skupini, ki je prejemala placebo in rešilno zdravljenje z midazolamom ter fentanilom) - bradikardija (14 % v skupini, ki je prejemala deksmedetomidin, v primerjavi s 4 % v skupini, ki je prejemala placebo in rešilno zdravljenje z midazolamom ter fentanilom)
English: Dexdor is not recommended for patient controlled sedation.
Slovenian: Zdravilo Dexdor ni priporočljivo za sedacijo, ki jo uravnava bolnik.
English: Your doctor will know how to treat you based on your condition.
Slovenian: V tem primeru bo vaš zdravnik na podlagi vašega stanja presodil, kakšno zdravljenje potrebujete.
English: In the age groups 1 months to 6 years, body weight-adjusted plasma clearance appeared higher but decreased in older children.
Slovenian: 6 let je bil plazemski očistek, prilagojen na telesno maso, večji, vendar se je zmanjšal pri starejših otrocih.
English: Dexdor contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodium-free'.
Slovenian: Zdravilo Dexdor vsebuje manj kot 1 mmol natrija (23 mg) na ml, kar v bistvu pomeni "brez natrija".
English: The most frequently reported adverse reactions with dexmedetomidine in procedural sedation are listed below (the protocols of phase III studies contained pre-defined thresholds for reporting changes in blood pressure, respiratory rate and heart rate as AEs).
Slovenian: Najpogosteje poročani neželeni učinki pri uporabi deksmedetomidina pri proceduralni sedaciji so navedeni spodaj (v protokolih študij faze III so imeli neželeni učinki - spremembe krvnega tlaka,
English: When Dexdor is used in an outpatient setting patients should normally be discharged into the care of a suitable third party.
Slovenian: Če se zdravilo Dexdor uporablja ambulantno, je treba ob odpustu bolnikov navadno poskrbeti, da jih spremlja ustrezna tretja oseba.
English: Cytochrome P-450 catalyses the formation of two minor circulating metabolites, 3-hydroxymethyl dexmedetomidine produced by hydroxylation at the 3-methyl group of dexmedetomidine and H-3 produced by oxidation in the imidazole ring.
Slovenian: Citokrom P-450 katalizira nastanek dveh manj pomembnih presnovkov v krvi, 3-hidroksmetil deksmedetomidina, ki nastane s hidroksilacijo na 3-metilni skupini deksmedetomidina, in H-3, ki nastane z oksidacijo imidazolskega obroča.